The European Union approved Tukysa for the treatment of HER2-positive localized advanced or metastasis breast cancer

Seagen International (Seagen) recently announced that the European Commission (EC) has approved the sale of its HER2 tyrosine kinase inhibitor (TKI) Tukysa for the treatment of HER2-positive localized advanced or metastasis breast cancer.
EC has approved Tukysa (tucatinib) combined with tukysa monoantigen and capedabin for the treatment of adult patients with advanced HER2-positive breast cancer who have received at least two previous treatments against HER2.
in the HER2CLIMB trial at Tukysa in Seagen, TKI and cratur bead monoantigen and carpedabin used to reduce the risk of disease progress in patients by 46%.
survival of patients in the Tukysa combined treatment group was also improved, with a 34 percent reduction in the risk of death. clay Siegall, chief executive of
Seagen, said: "Tukysa combination therapy is a milestone for patients with or without HER2-positive metastasis breast cancer with or without brain metastasis and can extend the overall survival of both patients.
we are pleased that Tukysa has now been approved in Europe and look forward to further cooperation with various countries to ensure that patients can use it in a timely manner."